MTG Ventures and Ohara Pharmaceutical backed the second close of the medical data modelling technology developer’s latest round, which stands at $12.4m.
Japan-based medical software producer Hacarus has increased its series B round to ¥1.3bn ($12.4m) with funding from investors including brand development firm MTG and pharmaceutical company Ohara Pharmaceutical.
The corporates joined Miyako Capital, Resona Capital and Chushin Venture Capital, respective subsidiaries of Kyoto University and banking groups Resona and Kyoto Chuo Shinkin Bank, as well as Parkinson Laboratories, a Parkinson’s disease-focused research firm formed by Ohara and industrial plating provider Shin-Etsu Riken.
Financial services firms Bank of Kyoto and Japan…
